OMS906 not checked

Omeros Corporation

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
4 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals”In the company’s words, NCT06298955 on ClinicalTrials.gov
Tested for
Paroxysmal Nocturnal Hemoglobinuria
Main trialPhase 2
“The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.”In the company’s words, NCT06298955 on ClinicalTrials.gov
Other names
zaltenibart

Other drugs for Paroxysmal Nocturnal Hemoglobinuria

All 23 drugs for Paroxysmal Nocturnal Hemoglobinuria

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Dec 2026 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
Phase 2Completed 10 Oct 2024 Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
Phase 2Terminated 14 Apr 2026 Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 1Completed 3 Nov 2025 Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow OMS906

Following is part of Solo: you see every change to OMS906 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in